Carclo smashes medium-term targets and unveils Precision 2030 growth plan

That looks rough at first glance, but context matters. Design & Engineering is project-driven, so annual swings are normal, and Carclo says a prior asset revitalisation cycle has now completed. More importantly, CTP operating profit still rose 21.9% to £15.1 million and margin improved to 15.4% from 11.6%.

That is the heart of the bull case here. The business is smaller than before, but healthier.

Speciality is quietly becoming a star performer

The Speciality division had a very good year. Revenue rose 12.5% to £16.0 million, operating profit increased 27.9% to £3.6 million and margin reached 22.4%.

Aerospace is doing the heavy lifting, with a third consecutive year of record orders. This is attractive business because once a part is qualified on an aircraft platform, supply can last for decades. That gives revenues a sticky, long-duration feel that investors usually like.

Carclo Precision 2030 growth plan: ambitious, but not reckless

Having finished the turnaround phase, Carclo is now moving into growth mode with its new Precision 2030 plan. The new targets are:

• Organic revenue growth of more than 8% compound annually across the plan period
• Net debt of less than 0.5x EBITDA by FY31
• New work to keep delivering at least 10% return on sales and 25% return on capital employed

I think these targets are ambitious but sensible. Management is not promising wild expansion at any cost. Instead, it is saying growth must still hit decent returns, which is exactly what shareholders should want.

The growth areas include drug delivery, wearables, pharma packaging, defence and local life sciences customers in Asia-Pacific. There is also a meaningful innovation push around proprietary tooling, materials and connected drug-delivery products.

The key point is this: Carclo is trying to grow in markets where qualification is hard, switching suppliers is risky and margins can stay high. That is a better strategy than competing in commoditised work.

Debt, pension and cash flow: the main issues investors still need to watch

Not everything in this update is clean and easy. Cash generated from operations dropped to £12.0 million from £19.1 million, and net debt rose to £23.9 million from £19.2 million.

Management says the increase was largely driven by a one-off additional pension contribution of £5.1 million in April 2025, plus annual pension contributions of £3.5 million and working capital outflows. That explanation is fair, but it does not make the cash drain disappear.

The pension remains the big overhang. The IAS 19 pension deficit was still £46.8 million at year end, although that was down from £51.7 million. On a technical provisions basis, the deficit improved to £52.9 million from £64.5 million at the last triennial valuation, so the direction is better.

Even so, this is still a serious liability for a business of Carclo’s size. It limits flexibility and helps explain why there is no dividend.

Refinancing looks helpful, but covenants still matter

Carclo refinanced into a £36.0 million asset-backed facility with BZ Commercial Finance DAC running to April 2028. At the year end there were no drawings under the revolving credit facility, leaving £9.0 million of headroom, subject to borrowing base limits.

The group says it remained compliant with its lender covenants throughout the year, and the board is comfortable on going concern. That is reassuring. Still, the company also disclosed that under a combined downside scenario it could face a temporary breach of its fixed charge cover ratio covenant, although management believes mitigation is available.

That is not a red flag on its own, but it is a reminder that Carclo is improved, not bulletproof.

Current trading and FY27 outlook: second-half weighting means patience required

The outlook is mixed. Aerospace demand remains strong, but parts of Life Sciences are softer, especially diagnostics, where a weaker respiratory virus season has reduced testing volumes and led some customers to adjust inventory.

Carclo expects that weakness to be temporary and says FY27 trading should be weighted towards the second half, with positive organic revenue growth for the full year. That is plausible, but it does mean investors may need patience if the first half looks subdued.

There is also customer concentration to keep in mind. The top five customers made up 70% of revenue, and one customer alone accounted for 32.4%. Long relationships are helpful, but concentration always adds risk.

What Carclo’s FY26 results mean for retail investors

My read is broadly positive. Carclo has delivered the hardest part of its recovery story: better margins, better returns and a more disciplined operating model. Hitting its 10% return on sales and 25% return on capital employed targets early is not cosmetic. It suggests the business has genuinely improved.

The negatives are clear too. Revenue is still down, cash conversion weakened, net debt rose and the pension deficit remains large. Underlying earnings per share also slipped slightly to 4.1p from 4.3p because finance costs were heavier, including non-cash pension and refinancing charges.

So this is not a perfect set of results. But it is a credible one.

If Carclo can now translate operational progress into sustained top-line growth without losing margin discipline, the Precision 2030 plan has real potential. For now, the story has moved from rescue to rebuild. That is progress, and in small-cap investing, real progress usually matters more than polished headlines.